Brief: Nanexa Says NEX-22 30 Mg Dose Well Tolerated In Phase I Study
07/04/2025 12:11
April 7 (Reuters) - Nanexa AB NANEXA.ST: NEX-22 30 MG DOSE WELL TOLERATED IN PHASE I STUDY Source text: ID:nMFN7gvP5h Further company coverage: NANEXA.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Nanexa AB
See all newsNanexa shares soar on €1.17 billion Novo Nordisk deal for injection technology
Brief: Nanexa And Novo Enter Global License, Collaboration Deal
Brief: Forge Nano And Nanexa To Develop Gmp-Compatible Ald Manufacturing Equipment
Brief: Nanexa Q2 Revenue Amounted To SEK 1.7 Million
Sweden's Nanexa Q1 revenue falls, loss widens